Incyte Corporation (NASDAQ:INCY) on Monday reported complete Phase 1/2 multidose data for latarcibart (VGA039), showing substantial reductions in bleeding episodes and a favorable safety profile in patients with von Willebrand disease (VWD).
VWD is the most common inherited bleeding disorder, affecting about 1% of the population.
It is caused by a deficiency or malfunction of the von Willebrand factor, a blood protein needed for platelets to clot properly.
Read Also: Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential Bleeding Rates Fell Across Patient Groups The analysis included all 16 enrolled patients, all of whom completed six doses of latarcibart, with maintenance treatment administered subcutaneously every four weeks as of May 5, 2026.
The investigational therapy produced a median 81% reduction in annualized bleeding rate (ABR) across all VWD types and bleeding categories, including serious gastrointestinal bleeds and hemophilia-like joint and muscle bleeds.
